-       Report 
- October 2025
-  269 Pages 
- Global 
   From       €5206EUR$5,850USD£4,582GBP 
            -       Report 
- April 2025
-  200 Pages 
- Global 
   From       €5660EUR$6,360USD£4,982GBP 
      €7074EUR$7,950USD£6,227GBP 
          -       Report 
- October 2024
-  100 Pages 
- Global 
   From       €5295EUR$5,950USD£4,661GBP 
          -       Report 
- December 2023
-  116 Pages 
- Global 
   From       €4004EUR$4,500USD£3,525GBP 
             Viberzi is a prescription medication used to treat irritable bowel syndrome with diarrhea (IBS-D) in adults. It is a type of gastrointestinal drug, which is a class of medications used to treat digestive disorders. Viberzi works by blocking certain receptors in the gut that cause pain and diarrhea. It is taken orally, usually once a day.
Viberzi is a relatively new drug, having been approved by the U.S. Food and Drug Administration (FDA) in 2015. It is manufactured by Allergan, a global    pharmaceutical company. Other companies in the gastrointestinal drug market include AbbVie, AstraZeneca, and Takeda Pharmaceuticals. Show Less   Read more